Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

Open access
Kelly, Aaron S, Bergenstal, Richard M, Gonzalez-Campoy, J, Katz, Harold, Bank, Alan J · 2012 · Cardiovascular Diabetology

Abstract

BACKGROUND: Glucagon like peptide-1 (GLP-1) receptor agonist treatment may improve endothelial function via direct and indirect mechanisms. We compared the acute and chronic effects of the GLP-1 receptor agonist exenatide vs. metformin on endothelial function in patients with obesity and pre-diabetes. METHODS: We performed a randomized, open-label, clinical trial in 50 non-diabetic individuals (mean age 58.5 ± 10.0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin. Microvascular endothelial function, assessed by digital reactive hyperemia (reactive hyperemic index: RHI), C-reactive protein (CRP), circulating oxidized LDL (oxLDL), and vascular cell adhesion molecule-1 (VCAM-1) were measured at baseline and 3-months. Seven subjects with IGT participated in a sub-study comparing the effects of pre-administration of exenatide and metformin on postprandial endothelial function. RESULTS: There were no differences for the change in RHI (Δ exenatide: 0.01 ± 0.68 vs. Δ metformin: -0.17 ± 0.72, P = 0.348), CRP, oxLDL, or VCAM-1 between exenatide and metformin treatment. Triglycerides were reduced more with exenatide compared to metformin (Δ exenatide: -25.5 ± 45.7 mg/dL vs. Δ metformin: -2.9 ± 22.8 mg/dL, P = 0.032). In the sub-study, there was no difference in postprandial RHI between exenatide and metformin. CONCLUSIONS: Three months of exenatide therapy had similar effects on microvascular endothelial function, markers of inflammation, oxidative stress, and vascular activation, as metformin, in patients with obesity and pre-diabetes. CLINICAL TRIALS REGISTRATION: This study is registered on http://www.clinicaltrials.gov/: NCT00546728.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2840-11-64

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Endothelial function before and after 3-months of treatment with either exenatide or metformin.
Figure 1 Endothelial function before and after 3-months of treatment with either exenatide or metformin.CC BY · PubMed Central
Figure 2 Serial endothelial function during the OGTT for control (no drug pre-administration) and pre-administration of either exenatide or metformin.
Figure 2 Serial endothelial function during the OGTT for control (no drug pre-administration) and pre-administration of either exenatide or metformin.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 98

Metadata

Authors
Kelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J., Katz, H., & Bank, A. J.
Affiliations
  • University of Minnesota (US)
  • Park Nicollet Clinic (US)
  • Allina Health (US)
  • United Heart and Vascular Clinic (US)
Corresponding author
Kelly, Aaron S
Venue
Cardiovascular Diabetology
Published
2012
Volume
11
Issue
1
Pages
64
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2096739965
Cited by
98
References
35
Citations by year
2026: 4 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 2 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 4 · 2017: 10 · 2016: 10 · 2015: 8 · 2014: 17 · 2013: 8 · 2012: 4
FWCI
9.42
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Park Nicollet Foundation
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
Keywords
exenatide, metformin, endothelial function, GLP-1 receptor agonists, obesity, prediabetes, impaired glucose tolerance, reactive hyperemia, C-reactive protein, oxidized LDL, VCAM-1, inflammation, oxidative stress, triglycerides
MeSH terms
Exenatide, Aged, Analysis of Variance, Blood Glucose, C-Reactive Protein, Endothelium, Vascular, Female, Glycated Hemoglobin, Humans, Hyperemia, Hypoglycemic Agents, Lipoproteins, LDL, Male, Metformin, Microcirculation, Middle Aged, Peptides, Prediabetic State, Time Factors, Venoms, Biomarkers, Treatment Outcome, Inflammation Mediators, Vascular Cell Adhesion Molecule-1, Upper Extremity, Obesity, Abdominal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. https://app.cochat.ai/papers/10.1186/1475-2840-11-64
The paper
Kelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J., Katz, H., & Bank, A. J. (2012). Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovascular Diabetology. https://doi.org/10.1186/1475-2840-11-64

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.